Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;10(4):813-816.
doi: 10.1038/s41564-025-01969-x.

Combining antibiotics to tackle antimicrobial resistance

William Hope  1   2 , Sumathi Nambiar  3 , Seamus O'Brien  4 , Michael Sharland  5 , David L Paterson  6 , Mo Yin  6   7 , Ian H Gilbert  8 , Michael Ferguson  8 , Sharon J Peacock  9 , Iain Buchan  10   11 , Nada Reza  12   13 , Vineet Dubey  12 , Christopher A Darlow  12   13 , Alessandro Gerada  12   13 , Alex Howard  12   13 ; Pre-X Investigators
Collaborators, Affiliations

Combining antibiotics to tackle antimicrobial resistance

William Hope et al. Nat Microbiol. 2025 Apr.

Erratum in

  • Author Correction: Combining antibiotics to tackle antimicrobial resistance.
    Hope W, Nambiar S, O'Brien S, Sharland M, Paterson DL, Yin M, Gilbert IH, Ferguson M, Peacock SJ, Buchan I, Reza N, Dubey V, Darlow CA, Gerada A, Howard A; Pre-X Investigators. Hope W, et al. Nat Microbiol. 2025 May;10(5):1258. doi: 10.1038/s41564-025-02003-w. Nat Microbiol. 2025. PMID: 40204877 No abstract available.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: W.H. holds or has recently held research grants with UKRI, EU (FP7, IMI-1, IMI-2), Wellcome, F2G, Spero Therapeutics, Antabio, Pfizer, Allecra, Bugworks, Phico Therapeutics, BioVersys and the Global Antimicrobial Research and Development Partnership (GARDP). He is (or has recently been) a consultant for Appili Therapeutics, F2G, Spero Therapeutics, Pfizer, GSK, Phico Therapeutics, Pulmocide and Mundipharma Research Ltd. He was a member of the Specialist Advisory Committee for GARDP (2020–2023), a member of the British Society for Antimicrobial Chemotherapy (BSAC) Breakpoint Committee (2020–2023), a member of Health Technology Appraisal (HTA) Prioritisation Committee for Hospital Care (2022–2024) and was the Specialty National Co-lead for Infection for the National Institute of Health Research (NIHR) (2020–2024). I.B. was Chief Data Scientist Advisory for AstraZeneca (2019–2023). S.N. is an employee of Johnson and Johnson; her views are her own and do not necessarily represent those of her employer. The other authors declare no competing interests.

References

    1. AMR-X Collaborators. Lancet Microbe 5, e500–e507 (2024). - DOI
    1. Antimicrobial Resistance Collaborators et al. Lancet 399, 629–655 (2022).
    1. Kerantzas, C. A. & Jacobs, W. R. mBio 8, e01586–16 (2017). - DOI - PubMed - PMC
    1. Poespoprodjo, J. R., Douglas, N. M., Ansong, D., Kho, S. & Anstey, N. M. Lancet 402, 2328–2345 (2023). - DOI - PubMed
    1. Goldstein, B. P. J. Antibiot. 67, 625–630 (2014). - DOI

LinkOut - more resources